Global Actinic
Keratosis Market To Reach Worth USD 8.91 Bn By 2022: High Disease Prevalence
And Associated Hoard To Prevent Skin Cancer To Drive The Market Growth
According to the
latest report published by Credence Research, Inc. “Actinic Keratosis Market
(Liquid Nitrogen Cryotherapy, Surgical Therapy, 5-aminolevulinic acid (ALA),
Methyl Aminolevulinate (MAL), 5-fluorouracil, Imiquimod, Ingenol Mebutate,
Diclofenac Sodium, Chemical Peels and Others) - Growth, Future Prospects and
Competitive Analysis, 2016-2022,” the actinic keratosis market was valued at
USD 6,561.8 Mn in 2015 and is expected to reach USD 8,909.7 Mn by 2022, with
the market progressing at a CAGR 4.35%from 2016-2022.
Browse the
full reportActinic Keratosis:Market Growth, Future Prospects and Competitive
Analysis, 2016-2022report at http://www.credenceresearch.com/report/actinic-keratosis-market
Market
Insights
Actinic keratosis (AK)
is characterized by skin papules, macules or plaques resulting from prolonged
exposure to harmful UV exposure and can result in squamous cell carcinoma. Risk
of developing actinic keratosis increases with advancing age and is
particularly higher in men as against women. About 5-20% of patients with
actinic keratosis lesions develop malignant and potentially fatal squamous cell
carcinomas.
Among the various
treatment methods available, destructive therapies such as liquid nitrogen
cryotherapy and surgical therapy constitute the gold standard for AK treatment.
In 2015, cryotherapy was the most commonly sought treatment by clinicians.
However, better clinical results of photodynamic therapy and growing preference
for treatments based on drug-device combination have urged both caregivers and
patients to opt for novel treatment methods that offer both advanced efficacy,
aesthetic benefits and reduced risk of future malignancies.
Topical treatment is a
prolonged treatment and comparatively more effective than other treatments but
patient compliance is the key issue that hinders the growth of this segment.
Photodynamic therapy is the fastest growing treatment throughout the forecast
period due to rising demand for non-invasive surgeries, and less treatment
sessions are the key factors expected to assist this market
North America is the
largest market for actinic keratosis treatment due to growing prevalence of AK,
better public awareness about occurrence of AK and associated risk of squamous
cell carcinoma. According to American Academy of Dermatology (AAD), approximately
60% of the Americans aged 40 year or above, Actinic Keratosis is predisposed to
develop having at least 1 AK lesion. Actinic keratosis is precursors of
squamous cell cancer. U.S. held the largest share in the actinic keratosis
market in 2015 owing to current prevalence of actinic keratosis in the
region.Asia Pacific is the fastest growing market for AK treatments. Australia
has the highest prevalence of actinic keratosis ranging between 40% to 60% in
adult population. Growing awareness in the region and rapid development in
healthcare infrastructure and healthcare expenditure are the key growth factors
in Asia Pacific actinic keratosis market.
This market is majorly
driven by wide presence of generic drugs and is moderately competitive.
Photodynamic therapy market has developed a niche with methyl aminolevulinate
and aminolevulinic acid drugs. Galderma and DUSA pharmaceuticals are the chief
players in this space. Some of the major players in the global actinic
keratosis market are Tolmar Pharmaceuticals, Inc, DUSA Pharmaceuticals, Inc.,
Valeant Pharmaceuticals International, Inc., Aqua Pharmaceuticals, LLC,
Galderma SA, Perrigo Company plc, LEO Laboratories, Apotex and others.
About Us:
Credence
Research is a worldwide market research and counseling firm that serves driving
organizations, governments, non legislative associations, and not-for-benefits.
We offer our customers some assistance with making enduring enhancements to
their execution and understand their most imperative objectives. Over almost a
century, we’ve manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith (Global Sales
Manager)
Address:
105 N 1st ST #429, SAN JOSE, CA 95103 US
Ph: 1-800-361-8290
